3篇
您的检索式：作者名="Anantharaman Vathsala"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | LIPID ABNORMALITIES IN CYCLOSPORINE-PREDNISONE-TREATED RENAL TRANSPLANT RECIPIENTS显示文摘 | ANANTHARAMAN VATHSALA RICHARD B. WEINBERG LINDA SCHOENBERG JOACHIM GREVEL RICHARD A. GOLDSTEIN CHARLES T. VAN BUREN RICHARD M. LEWIS BARRY D. KAHAN | 1989 | Transplantation1989，，1： | 1 |
| 2 | A retrospective Aliskiren and Losartan study in non-diabetic chronic kidney disease显示文摘AIM: To assess the efficacy of combined Aliskiren and Losartan vs high dose Losartan and Aliskiren alone in chronic kidney disease(CKD).METHODS: This is a retrospective study of 143 patients with non-diabetic CKD comparing combined Aliskiren(150 mg/d) with Losartan(100 mg/d) therapyvs High dose Angiotensin receptor blockers(ARB)(Losartan 200 mg/d) and the third group Aliskiren(150 mg/d) alone. This study involved only patient medical records. Entry criteria included those patients who had been treated with the above drugs for at least 36 mo within the 5 years period; other criteria included proteinuria of 1 g or more and or CKD Stage 3 at the start of the 36 mo period. The study utilised primary renal end points of estimated Glomerular Filtration Rate(e GFR) < 15 m L/min or end stage renal failure. RESULTS: Patients treated with high dose ARB compared to the other two treatment groups had significantly less proteinuria at the end of 36 mo(P < 0.007). All 3 groups had significant reduction of proteinuria(P < 0.043, P < 0.001). Total urinary protein was significantly different between the 3 groups over the 3-year study period(P = 0.008), but not e GFR. The changes in e GFR from baseline to each year were not significantly different between the 3 therapeutic groups(P < 0.119). There were no significant differences in the systolic and diastolic blood pressure between the 3 drug groups throughout the 3 years. The incidence of hyperkalemia(> 5.5 mmol/L) was 14.2%(7/49) in the Combined Aliskiren and ARB group, 8.7%(4/46) in the Aliskiren alone group and 6.3%(3/48) in the High dose ARB group(P < 0.001). CONCLUSION: This study in non-diabetic CKD patients showed that Combination therapy with Aliskiren and ARB was effective but was not safe as it was associated with a high prevalence of hyperkalaemia. | Keng-Thye Woo Hui-Lin Choong Kok-Seng Wong Han-Kim Tan Marjorie Foo Fook-Chong Stephanie Evan JC Lee Vathsala Anantharaman Grace SL Lee Choong-Meng Chan | 2013 | World Journal of Nephrology2013，2，4： | 1 |
| 3 | Engineering immunosuppressive drug-resistant armored(IDRA)SARS-CoV-2 T cells for cell therapy显示文摘Solid organ transplant(SOT)recipients receive immunosuppressive drugs(ISDs)and are susceptible to developing severe COVID-19.Here,we analyze the Spike-specific T-cell response after 3 doses of mRNA vaccine in a group of SOT patients(n=136)treated with different ISDs.We demonstrate that a combination of a calcineurin inhibitor(CNI),mycophenolate mofetil(MMF),and prednisone(Pred)treatment regimen strongly suppressed the mRNA vaccine-induced Spike-specific cellular response.Such defects have clinical consequences because the magnitude of vaccine-induced Spike-specific T cells was directly proportional to the ability of SOT patients to rapidly clear SARS-CoV-2 after breakthrough infection.To then compensate for the T-cell defects induced by immunosuppressive treatment and to develop an alternative therapeutic strategy for SOT patients,we describe production of 6 distinct SARS-CoV-2 epitope-specific ISD-resistant T-cell receptor(TCR)-T cells engineered using the mRNA electroporation method with reactivity minimally affected by mutations occurring in Beta,Delta,Gamma,and Omicron variants.This strategy with transient expression characteristics marks an improvement in the immunotherapeutic field and provides an attractive and novel therapeutic possibility for immunosuppressed COVID-19 patients. | Qi Chen Adeline Chia Shou Kit Hang Amy Lim Wee Kun Koh Yanchun Peng Fei Gao Jili Chen Zack Ho Lu-En Wai Kamini Kunasegaran Anthony Tanoto Tan Nina Le Bert Chiew Yee Loh Yun Shan Goh Laurent Renia Tao Dong Anantharaman Vathsala Antonio Bertoletti | 2023 | Cellular & Molecular Immunology2023，20，11： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员